Homology Medicines Inc (NASDAQ:FIXX) CFO W Bradford Smith sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $18.74, for a total value of $112,440.00. Following the sale, the chief financial officer now directly owns 6,000 shares in the company, valued at approximately $112,440. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
W Bradford Smith also recently made the following trade(s):
- On Thursday, August 1st, W Bradford Smith sold 6,000 shares of Homology Medicines stock. The shares were sold at an average price of $17.37, for a total value of $104,220.00.
- On Monday, July 1st, W Bradford Smith sold 6,000 shares of Homology Medicines stock. The shares were sold at an average price of $19.00, for a total value of $114,000.00.
Homology Medicines stock traded up $0.13 during midday trading on Friday, reaching $20.21. The company’s stock had a trading volume of 219,432 shares, compared to its average volume of 223,190. The stock’s 50-day simple moving average is $18.06 and its 200-day simple moving average is $21.68. Homology Medicines Inc has a 52-week low of $14.19 and a 52-week high of $31.80. The stock has a market capitalization of $882.84 million, a P/E ratio of -10.11 and a beta of 0.11.
A number of institutional investors have recently added to or reduced their stakes in the business. Aperio Group LLC purchased a new stake in Homology Medicines in the second quarter valued at about $34,000. Bank of America Corp DE raised its stake in Homology Medicines by 7.1% in the fourth quarter. Bank of America Corp DE now owns 30,439 shares of the company’s stock valued at $681,000 after buying an additional 2,027 shares during the last quarter. Bank of Montreal Can purchased a new stake in Homology Medicines in the second quarter valued at about $40,000. Cubist Systematic Strategies LLC purchased a new stake in Homology Medicines in the second quarter valued at about $42,000. Finally, Marshall Wace LLP purchased a new stake in Homology Medicines in the first quarter valued at about $74,000. Institutional investors own 56.06% of the company’s stock.
A number of equities research analysts have commented on the company. HC Wainwright set a $36.00 price target on Homology Medicines and gave the company a “buy” rating in a research note on Tuesday, June 11th. Canaccord Genuity set a $37.00 price target on Homology Medicines and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, Zacks Investment Research upgraded Homology Medicines from a “sell” rating to a “hold” rating in a research note on Tuesday, July 16th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $29.10.
About Homology Medicines
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Further Reading: How Do Mutual Funds Work?
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.